Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer Chemotherapy Update: Bevacizumab, Etoposide, and Cisplatin Regimen for Refractory Brain Metastases.

Literature DB >> 29276261

Cancer Chemotherapy Update: Bevacizumab, Etoposide, and Cisplatin Regimen for Refractory Brain Metastases.

Seth A Mayer¹, Dominic A Solimando², J Aubrey Waddell³.

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, email: waddfour@charter.net. Regimen Name: Bevacizumab, etoposide, and cisplatin (BEEP) Origin of Name: The regimen is named for the medications it contains: bevacizumab, etoposide, and cisplatin.

Entities: Chemical Disease

Year: 2017 PMID： 29276261 PMCID： PMC5735694 DOI： 10.1177/0018578717717622

Source DB: PubMed Journal: Hosp Pharm ISSN： 0018-5787

25 in total

1. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications.

Authors: Olga Geling; Hans-Georg Eichler
Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544

Review 2. Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Authors: P J Hesketh; M G Kris; S M Grunberg; T Beck; J D Hainsworth; G Harker; M S Aapro; D Gandara; C M Lindley
Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544

Review 3. Hepatotoxicity of chemotherapy.

Authors: P D King; M C Perry
Journal: Oncologist Date: 2001

4. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.

Authors: G Cocconi; R Lottici; G Bisagni; M Bacchi; M Tonato; R Passalacqua; C Boni; V Belsanti; P Bassi
Journal: Cancer Invest Date: 1990 Impact factor: 2.176

5. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy.

Authors: Yen-Shen Lu; Tom Wei-Wu Chen; Ching-Hung Lin; Dah-Cherng Yeh; Ling-Ming Tseng; Pei-Fang Wu; Kun-Ming Rau; Bang-Bin Chen; Ta-Chung Chao; Shu-Min Huang; Chiun-Sheng Huang; Tiffany Ting-Fang Shih; Ann-Lii Cheng
Journal: Clin Cancer Res Date: 2015-02-19 Impact factor: 12.531

Review 6. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.

Authors: P E Kintzel; R T Dorr
Journal: Cancer Treat Rev Date: 1995-01 Impact factor: 12.111

7. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.

Authors: Leora Horn; Suzanne E Dahlberg; Alan B Sandler; Afshin Dowlati; Dennis F Moore; John R Murren; Joan H Schiller
Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544

Review 8. Hepatotoxicity of chemotherapy.

Authors: Justin Floyd; Irfan Mirza; Bradley Sachs; Michael C Perry
Journal: Semin Oncol Date: 2006-02 Impact factor: 4.929